KAIROS HEALTH CAPITAL MANAGEMENT

Kairos Health Capital Management invests exclusively in healthcare, targeting digital health, health IT, and tech-enabled services companies. The firm concentrates on Seed through Series B stages, with a preference for direct equity positions that include board involvement. Its thesis centers on care delivery transformation, data interoperability, and workflow automation.

The firm's observed posture is direct investments, with principals taking active board or advisory roles with portfolio companies. There is no public record of the firm operating as a fund-of-funds or making passive LP commitments into third-party healthcare vehicles.

Given its single-sector mandate in healthcare, Kairos likely sources through founder networks within digital health, relationships with hospital systems, and connections to accelerators and incubators focused on health IT. The firm's operator-background principals suggest domain-specific referrals drive deal flow rather than broad inbound from intermediaries.

Kairos targets early-to-growth-stage companies, from Seed through Series B rounds. The firm's strategy favors entering at points where operational involvement can meaningfully influence product-market fit and go-to-market execution, rather than passive late-stage pre-IPO positions.

The firm's co-investment posture is not publicly documented. As a dedicated healthcare investor with a lean partnership structure, it may syndicate rounds with other specialist healthcare funds or generalist venture firms, but no specific co-investment patterns or club structures are reported in available records.

Specific named principals and the investment committee structure are not publicly disclosed. The firm's website and public filings do not surface individual decision-makers, and no LinkedIn presence provides personnel data. The lean profile suggests a small partnership with flat decision-making authority.

The primary investment geography is the United States. The firm may evaluate opportunities in Canada and select European markets where healthcare regulatory environments support the digital health thesis, but US-domiciled companies form the core of the strategy.